SCHEMBL15731000

SCHEMBL15731000

Cc1sc(NC(=O)c2ccc(Br)o2)c(C(N)=O)c1C

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 11/20 0.76
▸ KDM4E B2RXH2 8/20 0.76
▸ HPGD P15428 6/20 0.76
▸ KMT2A Q03164 6/20 0.76
▸ MAPT P10636 7/20 0.62
▸ RAB9A P51151 7/20 0.62
▸ NPC1 O15118 7/20 0.62
▸ SMN1; SMN2 Q16637 4/20 0.62
▸ HSD17B10 Q99714 4/20 0.60
▸ CASP1 P29466 3/20 0.60
▸ NPSR1 Q6W5P4 3/20 0.60
▸ TSHR P16473 2/20 0.60
▸ MAPK1 P28482 3/20 0.58
▸ POLB P06746 2/20 0.58
▸ TDP1 Q9NUW8 1/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ TP53 P04637 2/20 0.55
▸ NFKB1 P19838 1/20 0.55
▸ CASP7 P55210 1/20 0.55
▸ NFKB2 Q00653 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8289404 0.83 ALDH1A1 (0.80) ALDH1A1KDM4EHPGDKMT2AMAPT
SCHEMBL15281387 0.79 ALDH1A1 (0.63) ALDH1A1KDM4EHPGDKMT2AMAPT
SCHEMBL5794137 0.78 ALDH1A1 (0.78) ALDH1A1KDM4EHPGDKMT2AMAPT
SCHEMBL17916667 0.77 HPGD (0.70) ALDH1A1KDM4EHPGDKMT2AMAPT
SCHEMBL7004914 0.74 NPC1 (0.61) ALDH1A1KMT2AMAPTRAB9ANPC1
SCHEMBL14825171 0.72 PKM (0.63) ALDH1A1KDM4EHPGDKMT2AMAPT
SCHEMBL7003934 0.72 ALDH1A1 (0.70) ALDH1A1KDM4EHPGDKMT2AMAPT
SCHEMBL6997315 0.72 ALDH1A1 (0.60) ALDH1A1KDM4EHPGDKMT2AMAPT
SCHEMBL18180597 0.71 L3MBTL1 (0.66) ALDH1A1KDM4EHPGDKMT2AMAPT
SCHEMBL7902809 0.71 GRIN2C (1.00) ALDH1A1KDM4EHPGDKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9261497-B2 Method of treating cancer with modulators of SCFSkp2 NEW YORK UNIVERSITY (US) 2016-02-16 — — US disclosed
US-20140142120-A1 METHOD OF TREATING CANCER WITH MODULATORS OF SCFSkp2 NEW YORK UNIVERSITY (US) 2014-05-22 — — US disclosed
US-20140142120-A1 METHOD OF TREATING CANCER WITH MODULATORS OF SCFSkp2 NEW YORK UNIVERSITY (US) 2014-05-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140142120-A1 METHOD OF TREATING CANCER WITH MODULATORS OF SCFSkp2 SKP2, PACSIN2, MDM2 ALDH1A1 2386/4885KDM4E 785/4885HPGD 3807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback